Dept of Medicine, University of California San Diego, La Jolla, CA, USA.
Dept of Respiratory Diseases, University Hospitals of Leuven and Respiratory Division, Dept CHROMETA, KU Leuven - University of Leuven, Leuven, Belgium.
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01915-2018. Print 2019 Jan.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism and a major cause of chronic PH leading to right heart failure and death. Lung ventilation/perfusion scintigraphy is the screening test of choice; a normal scan rules out CTEPH. In the case of an abnormal perfusion scan, a high-quality pulmonary angiogram is necessary to confirm and define the pulmonary vascular involvement and prior to making a treatment decision. PH is confirmed with right heart catheterisation, which is also necessary for treatment determination. In addition to chronic anticoagulation therapy, each patient with CTEPH should receive treatment assessment starting with evaluation for pulmonary endarterectomy, which is the guideline recommended treatment. For technically inoperable cases, PH-targeted medical therapy is recommended (currently riociguat based on the CHEST studies), and balloon pulmonary angioplasty should be considered at a centre experienced with this challenging but potentially effective and complementary intervention.
慢性血栓栓塞性肺动脉高压(CTEPH)是肺栓塞的一种并发症,也是导致右心衰竭和死亡的慢性 PH 的主要原因。肺通气/灌注闪烁显像术是首选的筛选试验;正常扫描可排除 CTEPH。在灌注扫描异常的情况下,需要进行高质量的肺动脉造影以确认和定义肺血管受累情况,并在做出治疗决策之前进行。PH 可通过右心导管检查确诊,这也是治疗决策所必需的。除了慢性抗凝治疗外,每个 CTEPH 患者都应开始进行肺动脉内膜切除术的治疗评估,这是指南推荐的治疗方法。对于技术上不可手术的病例,推荐使用针对 PH 的药物治疗(目前基于 CHEST 研究的 riociguat),并且应在经验丰富的中心考虑球囊肺动脉成形术,这是一种具有挑战性但潜在有效且互补的介入治疗方法。